+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment for Alzheimers disease Where are we going?

Treatment for Alzheimers disease Where are we going?

European Neuropsychopharmacology 10(Supplement 3): S140-S141

(PDF emailed within 0-6 h: $19.90)

Accession: 035980165

Download citation: RISBibTeXText

DOI: 10.1016/s0924-977x(00)80038-3

Related references

Ganglioside alterations in alzheimers disease and treatment of alzheimers disease with gm 1. Neurobiology of Aging 11(1): 76, 1990

Mortality and Treatment Costs have a Great Impact on the Cost- Effectiveness of Disease Modifying Treatment in Alzheimers Disease - A Simulation Study. 2013

Enhanced binding to NMDA receptors in the striatum of Parkinsons disease, Alzheimers disease and mixed Parkinsons disease/Alzheimers disease patients. Society for Neuroscience Abstracts 19(1-3): 194, 1993

Preventive or therapeutic agents for Alzheimers disease a screening method of Alzheimers disease and Tau-protein kinase I originated from human being. Official Gazette of the United States Patent & Trademark Office Patents 1216(3): 2995, Nov 17, 1998

Methodology and initial mr evaluations in alzheimers disease a preliminary report from cerad consortium to establish a registry for alzheimers disease. Neurology 40(4 SUPPL 1): 227, 1990

SPECT in Alzheimers disease Perfusion patterns, demographics and correlations with the Alzheimers disease assessment scale-cognitive subscale. Neurology 52(6 SUPPL 2): A367-A368, April 12, 1999

PET amyloid imaging as a tool for early diagnosis and identifying patients Alzheimers disease at risk for progression to Alzheimers disease. Alzheimer's Research & Therapy 3(2), 2011

Apolipoprotein E levels in plasma and CSF from members of the Swedish Alzheimers disease APP 670/671 Mutation family and sporadic Alzheimers disease cases. Neurobiology of Aging 17(4 SUPPL ): S59, 1996

CD40 ligand is localized in astrocytes and is increased in Alzheimers disease and in animal models of Alzheimers disease and brain injury. Society for Neuroscience Abstracts 27(2): 2563, 2001

Autoradiographic study of galanin binding in the normal and Alzheimers disease brain Evidence for increased receptor occupancy in Alzheimers disease. Society for Neuroscience Abstracts 22(1-3): 204, 1996

Longitudinal assessment of probable alzheimers disease 2 year follow up data from the consortium to establish a registry for alzheimers disease cerad. Neurology 40(4 SUPPL 1): 450, 1990

Detection and measurement of alzheimers disease associated protein adap in cerebrospinal fluid csf an antemortem marker for alzheimers disease. Society for Neuroscience Abstracts 17(1-2): 1259, 1991

Why home health services are provided to Alzheimers disease patients in Californias Alzheimers disease program: an exploration. Home health care services quarterly4(2-3): 111-125, 1993

Clinical features and predictors of progression in patients with Alzheimers disease and with the Lewy body variant of Alzheimers disease. Neurology 50(4 SUPPL 4): A182, 1998

Autoradiographic study of iodoclonidine binding in normal and Alzheimers disease brain Evidence for preservation of alpha-2 adrenergic receptors in Alzheimers disease. Society for Neuroscience Abstracts 23(1-2): 1896, 1997